**Core tip:** This systematic review and meta-analysis included a large number of studies about clinical trials and preclinical experiments of bioartificial liver (BAL) support systems for treating patients and large animal models with acute liver failure. We summarized the characteristics of studies, BAL, and outcomes in all the studies and compared the pooled effect by meta-analysis including only randomized controlled trial studies regarding mortality after BAL among humans and large animals, respectively.

INTRODUCTION
============

Acute liver failure (ALF) is characterized by an acute episode of liver dysfunction in individuals without underlying chronic liver diseases, sometimes causing a rapid onset of encephalopathy and coagulopathy followed by multiorgan system failure. Patients with ALF have a high mortality ranging from 80% to 85%, approaching 90% among those with severe fulminant hepatic failure (FHF)\[[@B1]\]. The most effective treatment method for patients with ALF is liver transplantation, as it has increased the 5-year survival rate by 75%\[[@B2]\]. Although some patients might recover spontaneously, many would die during waiting for a compatible donor because of aggressive deterioration of liver function or development of cerebral edema, intracranial hypertension, and even irreversible brain damage. Thus, a liver support system must be developed to maintain a viable status of these patients prior to the transplantation.

During the past decades, several artificial devices for removing toxins from patients' blood through filtration and adsorption have improved clinical status in some cases. However, a meta-analysis of six randomized controlled trials (RCTs) concluded that artificial liver support systems might not reduce the mortality in ALF\[[@B3]\]. Moreover, the newly developed bioartificial liver (BAL) support systems that incorporate a hepatoma cell line or primary hepatocytes into a bioreactor when processing blood or plasma proved meaningful for prolonging the survival time of ALF animals in preclinical trials. Several types have been applied for the treatment of patients with ALF in phase I studies or controlled clinical trials, and improved neurological status and liver and renal functions, thus bridging to transplantation or spontaneous recovery\[[@B4]-[@B7]\]. However, the survival outcome and adverse effects of such alternative methods are controversial\[[@B3],[@B8]\].

In addition, the BAL has various types with different cell sources, cell mass, and culture methods, as well as architectural design such as the bioreactor, scaffold, and separation, which might be associated with the effect and safety of the BAL in treating ALF\[[@B9]\]. Furthermore, the BAL has been modified and renovated in preclinical experiments on large animals but has not been used in clinical trials\[[@B10]-[@B12]\], which caused a significant gap between clinical and preclinical studies.

One objective of our study was to investigate the characteristics of studies about BAL for ALF in both clinical trials and recent preclinical experiments on large animals. In particular, we looked at key indicators of the BAL, survival outcome, and adverse events regarding the treatment. Another objective was to evaluate the pooled effect of the BAL on mortality by conducting a meta-analysis of randomized controlled studies stratified among patients with ALF and large animals.

MATERIALS AND METHODS
=====================

This study was constructed following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The protocol has been registered in PROSPERO, an international prospective register of systematic reviews (Registration number: CRD42019133215).

Inclusion and exclusion criteria
--------------------------------

We included studies about any of the BAL for ALF, including all clinical trials, case reports, and RCTs in patients with ALF and preclinical experiments in large animals (monkeys, pigs, and dogs) published in the past 10 years. The language was limited to English.

The exclusion criteria were as follows: (1) Not focusing on the outcome of BAL, or the ALF group could not be separated from the other study populations such as patients with acute-on-chronic liver failure; (2) Duplicates of previous publications; (3) Based on incomplete data; and (4) Reviews, meta-analyses, comments, guidelines, letters, editorial articles, and project or conference summaries. If more than one study by the same author using the same data was published, either the study with the largest sample size or the most recently published study was included.

Literature search and selection
-------------------------------

By using a searching strategy and filter that combined keywords or subjects about BAL and ALF, which had been pre-tested and improved repeatedly, we searched the Cochrane Library, PubMed, and EMbase to identify eligible articles till March 6, 2019 according to the inclusion and exclusion criteria, by setting the following key elements (Patients: ALF; Intervention: BAL; Comparison: None; Outcome: including but not limited to mortality, bridging time, liver and renal function; keywords used for literature search are shown in [Supplementary-material](Supplementary-material)). Literature about preclinical experiments in large animals was limited to papers published in the past 10 years. The references used in the eligible articles were also reviewed to examine other potential sources.

Teams of paired reviewers who were trained and knowledgeable about the study screened the literature independently. We screened the title and keywords first and excluded unqualified studies according to the predefined criteria. Then, we read the abstracts and full texts carefully to further exclude unqualified literature. The decision to exclude studies was determined by two reviewers. Inconsistent results were resolved either by discussion or decided by a third reviewer. Finally, the remaining studies were enrolled to be reviewed and analyzed. The flow chart of the study selection is shown in Figure [1](#F1){ref-type="fig"}.

![Flow chart of study selection.](WJG-25-3634-g001){#F1}

Data extraction
---------------

We extracted the following information from each eligible article: (1) basic information of the included studies, including the publication year, title of the article, journal along with impact factor in 2018, country of the first author, study setting, study type (clinical trial, case report, or preclinical experiment), and data sources (full text and abstract); (2) detailed information of clinical trials in humans, including the type of BAL \[*e.g*., HepatAssist, extracorporeal liver assist device (ELAD), academic medical center (AMC)-BAL, modular extracorporeal liver support (MELS), novel bioartificial liver support system (BLSS), radial-flow bioreactor (RFB)-BAL, and hybrid bioartificial liver (HBAL)\], whether hybrid or not, cell sources (*e.g*., porcine hepatocytes, C3A cells, or primary human hepatocytes), cell mass, sample size, ALF subtype \[fulminant hepatic failure (FHF) or primary nonfunction (PNF)\], age and sex of subjects, disease etiology \[*e.g*., PNF, viral, indeterminate, autoimmune, Acetaminophen (AO), and ischemic\], BAL treatment time, outcomes (*i.e*., bridging time, orthotopic liver transplantation, death events, and recovery), follow-up time, stable or unstable hemodynamics, effects on liver and renal functions, hematologic and coagulative parameters, encephalopathy index, neurological status, adverse events during treatment (*e.g*., transitory hypotension), and porcine endogenous retrovirus (PERV) test result; (3) data of preclinical experiment on large animals, including animal species (*e.g*., pig, canine, and monkey), number of animals, sex (female and male), weight (kg), inducer of acute liver failure (*e.g*., D-galactosamine, hepatic artery ligation, surgical ligation of all blood flow to the liver, α-amanitin, and lipopolysaccharide), type of BAL (*e.g*., FBBAL, HBAL, HBALSS, SRBAL, hiHep-BAL, and UCLBAL), cell sources (*e.g*., alginate-chitosan encapsulated primary porcine hepatocytes, co-cultured pig hepatocytes, bone marrow mesenchymal stem cells, human hepatic CL-1 cells grown in microgravity culture, HiHeps, and three-dimensional HepG2-cell spheroids), cell mass, bioreactor (*e.g*., choanoid fluidized bed bioreactor, multi-layer ﬂat-plate bioreactor anionic resin adsorption column, fluidized-bed bioreactor, perfusion bioreactor, spheroid reservoir, and packed-bed bioreactor), treatment time, survival time or rate at a specific time point, other effects such as ammonia level, and PERV test result.

For data extraction and scoring, paired reviewers conducted the survey independently on the basis of the literature database and recorded the necessary information. The results of the paired reviewers were cross-checked, and disagreements were resolved by discussion or decided by a third reviewer.

Statistical analysis
--------------------

We conducted description analyses of the study characteristics of clinical trials and preclinical experiments on large animals by using the absolute numbers and percentages of the qualitative variables, and mean \[standard deviation (SD)\] or median (percentile) of the quantitative data. The bias risk of the included RCT studies was assessed according to the Cochrane assessment method for RCTs, while risk of non-RCT studies was assessed according to the Newcastle-Ottawa Quality Assessment Scale for cohort studies.

By selecting clinical RCTs and preclinical RCT experiments with survival outcome (death event) recorded at a specific time, we combined the effect of selected studies on the relative ratio (RR) scale by performing a meta-analysis with a random effect model and assigning weights according to the estimated variance. The heterogeneity of the included studies was also tested, with Q-test significance (*P \<* 0.05) or *I^2^ \>* 50% indicating that heterogeneity existed between studies. The overall RR and 95% confidence interval (CI) were calculated. We also conducted sensitivity analyses to examine the impact of using alternative effect measures (odds ratio *vs* relative ratio), pooling methods \[Peto *vs* Mantel-Hanszel (M-H)\], and statistical models (fixed- *vs* random-effects). Begg's funnel plot was also used to evaluate the publication bias.

All the statistical analyses were performed with SPSS 23.0 (IBM Corp. Armonk, NY, United States) and Review Manager 5.3 (RevMan, the Cochrane Collaboration, Oxford, England).

RESULTS
=======

We identified 215 studies preliminarily, and then excluded 67 unrelated or ineligible articles, 34 articles about artificial liver support system, 14 articles about *in vitro* function evaluation, 1 duplicate article, 4 articles with unavailable data, and 65 reviews. We finally included 30 articles in the analyses, of which 18 were human clinical trials\[[@B6],[@B7],[@B13]-[@B28]\] (only 2 were RCT studies\[[@B6],[@B7]\]) and 12 were preclinical experiments in large animals\[[@B5],[@B10]-[@B12],[@B29]-[@B36]\].

Among the 30 articles, 94.4% (17/18) were clinical trials published before 2005, with only 1 phase I clinical trial published in 2018 (only abstract available). Studies about preclinical experiments in large animals in the recent 10 years accounted for 40% of the articles (12/30). The median (P~25~-P~75~) impact factor (IF) of the journals was 4.04 (2.60-9.20), with 8 articles having an IF \< 3 and 5 having an IF \> 10. Approximately two-thirds of the studies were conducted by authors in the United States (11/30) and China (8/30). One RCT study was done in England and published in *Hepatology* in 1996\[[@B7]\] while the other one was performed in 11 United States and 9 European sites by United States researchers and published in *Annals of Surgery* in 2004\[[@B6]\]. More than one-third (12/30) of the studies were about hybrid support systems (*e.g*., HBAL, MELS, HBALSS, and HepatAssist), distributed in 9 clinical trial studies and 3 preclinical experimental studies. The available data that we analyzed were mostly from full texts (29/30), and 1 abstract of clinical trial was also included considering the limited number of eligible studies in humans and the availability of valuable information in the abstract (as shown in [Supplemental Table 1](Supplemental Table 1)).

###### 

Characteristics of bioartificial liver support system and subjects of clinical trials

  **ID**                               **Publication year**   **Type of trial**                                  **BAL system**                                            **Subject**                                                                                                                                                                        
  ------------------------------------ ---------------------- -------------------------------------------------- --------------------------------------------------------- ------------- -------------------------------------------- -------------------- ------------ ---------------- ------------- ------------------------------------------------------ --------------------------------------------------------------------------------
  1                                    1994                   Non-controlled trial                               HepatAssist                                               Yes           Porcine hepatocytes                          6 × 10^9^            7            FHF 6 PNF 1      10-58         4M:3F                                                  PNF 1 ; Virus 1; AO 2; Indeterminate 3
  2                                    1997                   Non-controlled trial                               HepatAssist                                               Yes           Porcine hepatocytes                          5 × 10^9^            21           FHF 18           36.1 ± 3.4    7M:11F                                                 Virus 4; Indeterminate 8; AO 4; Ischemic 2
  PNF 3                                48.3 ± 11.2            1M:2F                                              Virus 1; Indeterminate 1; Autoimmune 1                                                                                                                                                                                                       
  3                                    2010                   Non-controlled trial                               HepatAssist                                               Yes           Porcine hepatocytes                          5 × 10^9^            18           FHF 15           10-56         10M;5F                                                 Indeterminate 7; Virus 3; AO 4; Ischemic 1
  PNF 3                                26-58                  1M:2F                                              Indeterminate 1; Virus 1; Autoimmune 1;                                                                                                                                                                                                      
  4                                    2002                   Non-controlled trial                               HepatAssist                                               Yes           Porcine hepatocytes                          5 × 10^9^            10           FHF 10           31            4M:6F                                                  Indeterminate 6; Virus 2; Wilson 1; Pyrazinamide 1
  5                                    1994                   Non-controlled trial                               ELAD                                                      No            C3A cells                                    200 g                11           FHF 10 PNF 1     38.5 ± 18.1   5M:6F                                                  Idiopathic 1; Virus 3; AO 2; INH 1; FIAU 3; Anhepatic 1
  6                                    2002                   Non-controlled trial                               ELAD                                                      No            C3A cells                                    300-400g             5            FHF 5            22.2 ± 9.4    2M:3F                                                  asparaginase toxicity 1; Indeterminate 3; Autoimmune 1
  7                                    2002                   Phase I trial                                      AMC-BAL                                                   No            Porcine hepatocytes                          11.9 × 10^9^         7            FHF 7            34.3 ± 15.2   2M:5F                                                  Virus 4; AFLP 1; Indeterminate 2
  8                                    2003                   Case report                                        AMC-BAL                                                   No            Porcine hepatocytes                          10 × 10^9^           1            FHF              35            F                                                      Virus 1
  9                                    1996                   Non-controlled trial                               NR                                                        No            Porcine hepatocytes                          5 × 10^9^            12           FHF 11 PNF 1     37.2 ± 15.5   6M:6F                                                  Indeterminate 4; AO 2; Virus 3; Ischemic Failure 1; Autoimmune 1; PNF 1
  10                                   2003                   Phase I trial                                      MELS                                                      Yes           Porcine hepatocytes; non-parenchymal cells   (1.8-4.4) × 10^10^   8            FHF 8            34.3          1M:7F                                                  Rug-related 2; Virus 3; Indeterminate 3
  11                                   2003                   Case report                                        MELS                                                      Yes           Human hepatocytes                            470 g                1            PNF              26            F                                                      Intoxication with amanita phalloides
  12                                   2002                   Case report                                        BLSS                                                      No            Porcine hepatocytes                          70-100 g             1            FHF              41            F                                                      Indeterminate 1
  13                                   2002                   Non-controlled trial                               RFB-BAL                                                   No            Porcine hepatocytes                          200-230 g            7            FHF 4 PNF 3      37.4 ± 18.4   5M:2F                                                  Virus 3; PNF 3; Liver trauma 1
  14                                   2003                   Non-controlled trial                               HBAL                                                      Yes           Porcine hepatocytes                          1.0 × 10^9^          12           FHF 12           41.8 ± 13.0   9M:3F                                                  Virus 12
  15                                   1999                   Non-controlled trial                               HepatAssis                                                Yes           Porcine hepatocytes                          5 × 10^9^            8            FHF 8            33.4 ± 11.0   1M:7F                                                  AO 8
  16[1](#T1FN1){ref-type="table-fn"}   2018                   Phase 1/2a Trial                                   LifeLiver BAL                                             NR            Porcine hepatocytes spheroids                NR                   8            FHF 8            NR            NR                                                     NR
  17                                   1996                   Pilot-Controlled Trial                             ELAD                                                      No            C3A cells                                    400 g                Group-1 17   FHF 17           30            6M:3F *vs* 3M:5F[2](#T1FN2){ref-type="table-fn"}       AO 5, Virus 3, ATB 5 *vs* AO 6, Virus 1[2](#T1FN2){ref-type="table-fn"}; ATB 1
  Group-2 7                            FHF 7                  0M:3F *vs* 3M:1F[2](#T1FN2){ref-type="table-fn"}   AO 3 *vs* AO 3, Virus 1[2](#T1FN2){ref-type="table-fn"}                                                                                                                                                                                      
  18                                   2004                   RCT                                                HepatAssist                                               Yes           Porcine hepatocytes                          7 × 10^9^            171          FHF 147 PNF 24   37            26M:60F *vs* 25M:60F[2](#T1FN2){ref-type="table-fn"}   Known causes 83, Indeterminate 64

Data from abstract;

Intervention *vs* control; NA: Not applicable; NR: Not reported; Sex: Male (M) and Female (F); ELAD: Extracorporeal liver assist device; BAL: Bioartificial liver; AMC-BAL: Academic medical center bioartificial liver ; MELS: Modular extracorporeal liver support; BLSS: Novel bioartificial liver support system; RFB-BAL: Radial-flow bioreactor bioartificial liver; HBAL: Hybrid bioartificial liver; FBBAL: Fluidized bed bioartificial liver; HBALSS: Hybrid bioartificial liver support system; PNF: Primary nonfunction; FHF: Fulminant hepatic failure; AO: Acetaminophen; INH: Isoniazid; FIAU: Fialuridine; AFLP: Acute fatty liver of pregnancy; ATB: Anti-tuberculous hepatotoxicity; PERV: Porcine endogenous retrovirus; RCT: Randomized controlled trial.

Characteristics of the BAL, subjects, outcomes, and adverse events in the clinical trials
-----------------------------------------------------------------------------------------

From the 18 clinical trials, 332 patients with ALF were included, with 295 cases of FHF subtypes and 37 cases of PNF subtypes. The mean age was 35.4 years, and females accounted for 69.4% of the patients according to the reported data. Most of the disease etiologies were indeterminate (103 cases), viruses (45 cases), and AO (33 cases). The types of BAL included HepatAssist (6 cases), ELAD (3 cases), AMC-BAL (2 cases), MELS (2 cases), BLSS (1 case), RFB-BAL (1 case), HBAL (1 case), Lifeliver (1 case), and BAL (1 case), and in one case the BAL type was unclear; of these 9 were hybrids and 8 were non-hybrids. Most of the cells were sourced from porcine hepatocytes (14/18), followed by C3A cells (3/18) and primary human hepatocytes (1/18). The mean cell mass was approximately 9 × 10^9^ (Table [1](#T1){ref-type="table"}).

The mean treatment time was around 25 h. Among the 317 reported patients, 201 received orthotopic liver transplant (OLT) and 57 recovered without OLT. The mean survival rate in the OLT group was 93%, with the follow-up period ranging from 7 days to 62 months. Hemodynamics were stable in all patients. These results show that BAL improved liver and renal functions in all the patients, except 3 with PNF\[[@B6],[@B14],[@B15]\], in terms of the different biochemical parameters, with decreased ammonia, bilirubin, and transaminase levels in 12, 12, and 10 studies, respectively. Other meaningful indicators were reduced, including lactate ALB, BUN, and creatinine levels. By examining prothrombin time (PT), international normalized ratio, or other parameters, 9 studies found improvements in hematological and coagulative status. Ten of 12 reported studies showed an improvement in encephalopathy index. Thirteen of 16 reported studies showed improvements in neurological indicators, showing decreased intracranial pressure (ICP) and increased cerebral perfusion pressure, Glasgow coma score, and comprehensive level of consciousness score. In 3 studies on ALF subtypes, the encephalopathy index and neurological indicators showed improvements in patients with FHF but not in patients with PNF\[[@B6],[@B14],[@B15]\]. However, one case report of a patient with PNF showed improvement in the neurological status with a change in coma stage from IV to I after BAL treatment\[[@B22]\] (Table [2](#T2){ref-type="table"}).

###### 

Outcomes and adverse events after treating by bioartificial liver support system in clinical trials

  **ID**                                         **Treating time**                                **Bridging** **time**                        **OLT /total**                                     **SR of OLT**                                  **SR of no OLT**                               **Recovery without OLT**                     **Follow-up time**   **Hemodynamics**                                              **Liver and renal function**                                                             **Hematologic and coagulation**    **Encephalopathy index**   **Neurologic**                               **Adverse events**                                                           **PERV test**
  ---------------------------------------------- ------------------------------------------------ -------------------------------------------- -------------------------------------------------- ---------------------------------------------- ---------------------------------------------- -------------------------------------------- -------------------- ------------------------------------------------------------- ---------------------------------------------------------------------------------------- ---------------------------------- -------------------------- -------------------------------------------- ---------------------------------------------------------------------------- ----------------
  1                                              1.6 × 6 h                                        24 h                                         7/7                                                100%                                           NA                                             NA                                           NR                   Stable                                                        Decreased: ammonia; transaminases                                                        Decreased: Fibrinogen              Improved                   Decreased: ICP Increased: CPP                None                                                                         NR
  2                                              2.1 × 6 h                                        45.3 h                                       16/18                                              100%                                           50%                                            1                                            NR                   Stable                                                        Decreased: ammonia; ALB; transaminases; bilirubin; BUN; creatinine Increased: glucose    Not improved                       Improved                   Decreased: ICP; Increased: CPP; GCS; CLOCS   Transient hypotension                                                        NR
  1.6 × 6 h                                      83.0 h                                           3/3                                          100%                                               NA                                             NA                                             NR                                           Stable               Decreased: transaminases; bilirubin; ALB Increased: glucose   Not improved                                                                             Not improved                       Not improved                                                                                                                                         
  3                                              1.8 × 6 h                                        38.6 h                                       14/15                                              100%                                           100%                                           1                                            2-62 m               Stable                                                        Decreased: ammonia; bilirubin; transaminases; ALB; BUN; creatinine; Increased: Glucose   Not improved                       Improved                   Decreased: ICP; Increased: CLOCS             None                                                                         Negative (5 y)
  1.7 × 6 h                                      21 h-8 d                                         3/3                                          100%                                               NA                                             NA                                             2-62 m                                       Stable               Not improved                                                  Not improved                                                                             Improved                           Not improved                                                                                                                                         
  4                                              1.9 × 6 h                                        46 h                                         10/10                                              80%                                            NA                                             NA                                           24.5m                Stable                                                        Decreased: bilirubin; transaminases                                                      Decreased: Platelets; Fibrinogen   Improved                   Increased: GCS; CLOCS                        Bleeding; transitory hypotension                                             Negative
  5                                              52.6 h                                           40.8 h                                       4/11                                               100%                                           14%                                            1                                            10 d                 Stable                                                        Improved                                                                                 NR                                 Improved                   Improved                                     Transitory hypotension                                                       NA
  6                                              50.8 h                                           50.8 h                                       5/5                                                80%                                            NA                                             NA                                           30 d                 Stable                                                        Improved                                                                                 NR                                 Not improved               Not improved                                 None                                                                         NA
  7                                              18.9 h                                           NR                                           6/7                                                100%                                           100%                                           1                                            18 m                 Stable                                                        Decreased: bilirubin; ammonia                                                            NR                                 NR                         Improved                                     Transitory hypotension                                                       Negative -18 m
  8                                              35 h                                             35 h                                         1/1                                                100%                                           NA                                             NA                                           15 m                 Stable                                                        Decreased: bilirubin; ammonia; lactate                                                   Not improved                       NR                         Improved                                     NR                                                                           Negative 12 m
  9                                              1.7 × 6 h                                        39.3 h                                       12/12                                              100%                                           NR                                             NR                                           NR                   Stable                                                        Decreased: bilirubin; ammonia; transaminases; Increased: glucose                         Not improved                       Improved                   Decreased: ICP; Increased: CPP; CLOCS        None                                                                         NR
  10                                             27.3 h                                           NR                                           8/8                                                100%                                           NR                                             NR                                           3y                   Stable                                                        Decreased: bilirubin; ALB                                                                Decreased: platelets               Improved                   NA                                           Decreased body temperature                                                   Negative 3 y
  11                                             79 h                                             79 h                                         1/1                                                100%                                           NR                                             NR                                           1y                   Stable                                                        Decreased: lactate; BUN; creatinine                                                      Improved                           Improved                   Improved                                     Decreased body temperature                                                   NA
  12                                             12 h                                             7 d                                          NA[1](#T2FN1){ref-type="table-fn"}                 NA[1](#T2FN1){ref-type="table-fn"}             NA[1](#T2FN1){ref-type="table-fn"}             NA[1](#T2FN1){ref-type="table-fn"}           7d                   Stable                                                        Decreased: lactate; ammonia; transaminases                                               Improved                           NR                         Not improved                                 Hypoglycemia                                                                 NR
  13                                             11.7 h                                           11.7 h                                       6/7                                                83%                                            0%                                             0                                            NA                   Stable                                                        Decreased: bilirubin; transaminase; ammonia; lactate; urea                               Improved                           NR                         Improved                                     None                                                                         Negative 180 d
  14                                             1.1 × 6 h                                        NR                                           NA[2](#T2FN2){ref-type="table-fn"}                 NA[2](#T2FN2){ref-type="table-fn"}             NR                                             NR                                           1 m                  Stable                                                        Decreased: bilirubin; transaminase; ammonia                                              Improved                           NR                         Improved                                     None                                                                         NR
  15                                             2.9 × 6 h                                        NR                                           3/8                                                100%                                           100%                                           5                                            NR                   Stable                                                        Decreased: ammonia; bilirubin; transaminases; BUN; creatinine                            Improved                           Improved                   Decreased: ICP Increased: CLOCS              None                                                                         NR
  16                                             NR                                               NR                                           2/6                                                100%                                           75%                                            3                                            NR                   NR                                                            Decreased: ammonia                                                                       Not improved                       NR                         Improved                                     Coagulopathy pneumonia, sepsis, and diseased progression                     Negative
  17                                             72 (3-168) h                                     NR                                           2/9 *vs* 2/8[3](#T2FN3){ref-type="table-fn"}       50% *vs* 50%[3](#T2FN3){ref-type="table-fn"}   6/7 *vs* 5/6[3](#T2FN3){ref-type="table-fn"}   6 *vs* 5[3](#T2FN3){ref-type="table-fn"}     NR                   Stable                                                        Decreased ammonia                                                                        Improved                           NR                         NR                                           Tachypnoeic; tachycardic; pyrexial; disseminated intravascular coagulation   NA
  1/3 *vs* 1/4[3](#T2FN3){ref-type="table-fn"}   100% *vs* 100%[3](#T2FN3){ref-type="table-fn"}   0% *vs* 0%[3](#T2FN3){ref-type="table-fn"}   0 *vs* 0[3](#T2FN3){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  18                                             17.4 h                                           5 d *vs* 3 d                                 45/85 *vs* 49/86[3](#T2FN3){ref-type="table-fn"}   89% *vs* 80%[3](#T2FN3){ref-type="table-fn"}   50% *vs* 38%[3](#T2FN3){ref-type="table-fn"}   20 *vs* 14[3](#T2FN3){ref-type="table-fn"}   30 d                 Stable                                                        Decreased bilirubin                                                                      Not improved                       NR                         Not improved                                 None                                                                         Negative 12 m

Suitable liver was available for OLTx during that time.

Simultaneous HBAL 1/7 died; nonsimultaneous HBAL 2/5 died.

Intervention *vs* control. NA: Not applicable; NR: Not reported; SR: Survival rate; OLT: Orthotopic liver transplantation; ALB: Albumin; BUN: Blood urea nitroge; ICP: Intracranial pressure; CPP: Cerebral perfusion pressure; GCS: Glasgow coma score; CLOCS: Comprehensive level of consciousness score; PERV: Porcine endogenous retrovirus.

During BAL treatment, 9 studies reported adverse events such as transient hypotension, decreased body temperature, tachycardia, pyrexia, and hypoglycemia, which had no clinical significance and resolved in all. PERV test results in 8 reported studies were all negative (Table [2](#T2){ref-type="table"}).

Characteristics of the BAL, animal, and outcomes in the preclinical experiments with large animals
--------------------------------------------------------------------------------------------------

Of 12 studies that performed preclinical experiments with pigs (8 studies, 160 animals), monkeys (2 studies, 45 animals), and canines (2 studies, 40 animals), the proportions of male and female animals were 45.3% (111/245) and 30.2% (74/245), respectively. Inducers included D-galactosamine in 7 studies (145 animals)\[[@B5],[@B12],[@B29]-[@B33]\], surgical operation in 3 studies (53 animals)\[[@B11],[@B34],[@B35]\], 85% hepatectomy in 1 study (18 animals)\[[@B36]\], and α-amanitin and lipopolysaccharide in 1 study (30 animals)\[[@B10]\] (Table [3](#T3){ref-type="table"}).

###### 

Characteristics of preclinical experiments on large animals in past 10 years

  **ID**   **Year**   **Animal**          **BAL system**   **Outcomes**   **Test for PERV**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  -------- ---------- ------------------- ---------------- -------------- ------------------- -------------------------------------------------- ----------- ------------------------------------------------------------------------ -------------- -------------------------------------------------------------------- ------ -------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- -------------------
  19       2011       Pig                 30               M              10-15               D-galactosamine                                    FBBAL       Alginate-chitosan encapsulated primary porcine hepatocytes               5 × 10^9^      Choanoid fluidized bed bioreactor                                    6 h    Survival time: BAL 72.9 ± 4.72 h Sham BAL 54.6 ± 4.09 h Control 54.8 ± 3.98 h                                                                                  Decreased: lactate; glucose                                                   NR
  20       2012       Canine              32               NR             10-15               D-galactosamine                                    HBAL        Co-cultured porcine hepatocytes and bone marrow mesenchymal stem cells   1x 10^10^      Multi-layer ﬂat-plate bioreactor + anionic resin adsorption column   3 h    7 day survival: HBAL 7/8 BAL 5/8 NBAL 4/8 Control 3/8                                                                                                          Decreased: transaminases; LDH; ammonia; bilirubin; PT Increased: ALB          Negative (7 d)
  21       2013       Pig                 13               F              25-30               Hepaticartery ligation                             NA          Alginate-encapsulated HepG2cell-spheroids                                5 × 10^10^     Fluidised-bed bioreactor                                             7 h    Survival time: BAL 10.5 ± 20.7 h SBAL 8.6 ± 21.4 h                                                                                                             Decreased: ICP; ammonia; Increased: bilirubin; acidosis                       NR
  22       2014       Cynomolgus monkey   15               M              6.5-7.0             D-galactosamine                                    HBALSS      Human hepatic CL-1 cells grown in microgravity culture                   4 × 10^9^      Perfusion bioreactor                                                 6 h    Survival time: 128 h BAL 5/10 Control 0/5                                                                                                                      Decreased: bilirubin; TBA; BUN; Cr; ammonia; Fischer indices Increased: ALB   NR
  23       2015       Canine              8                NR             10-13               D-galactosamine                                    HBAL        Co-cultured porcine hepatocytes and bone marrow mesenchymal cells        1 × 10^10^     Multi-layer ﬂat-plate bioreactor + anionic resin adsorption column   6 h    1 year survival: 7/8                                                                                                                                           Decreased: transaminases; PT; bilirubin; LDH; ammonia; Increased: ALB         Negative (1 year)
  24       2015       Pig                 18               F              45                  D-galactosamine                                    SRBAL       Porcine hepatocytes spheroids                                            200 g          Spheroid reservoir                                                   24 h   Survival 90 h (%) ST 0/6, 0% ST + Non-cell 1/6,17% ST + SRBAL 5/6, 83%                                                                                         Decreased: ammonia; ICP; brain water content                                  NR
  25       2016       Pig                 21               M              10-15               D-galactosamine                                    FBBAL       Alginate-chitosan encapsulated porcine hepatocytes                       5 × 10^9^      Choanoid fluidized bed bioreactor                                    6h     Survival time: FBBAL 70.4 ± 11.5 h Sham FBBAL 51.6 ± 7.9 h Control 49.3 ± 6.6 h                                                                                Decreased: PCs; LPCs; FAs; SM; Increased: CBAs                                NR
  26       2016       Pig                 20               NR             15-25               D-galactosamine                                    HiHep-BAL   HiHeps                                                                   3 × 10^9^      Multi-layer radial-ﬂow bioreactor                                    3h     Survival 7 d: hiHep-BAL 7/8 Empty-BAL 1/6 No-BAL 0/6                                                                                                           Decreased: transaminase ammonia; bilirubin; PT                                NR
  27       2017       Pig                 25               F              30-35               Surgical ligation of all blood flow to the liver   UCLBAL      3-dimensional (3D) HepG2-cell spheroids                                  7.3 × 10^10^   Fuidised bed bioreactor                                              6h     Survival time: Control-BAL 7.04 ± 1.9h, *n* = 15 Cell-BAL 8.21 ± 2.3 h, *n* = 13                                                                               Decreased: PT; INR; ICP; ammonia                                              NR
  28       2017       Pig                 15               M              45-55               Complete hepatic inflow devascularization          NA          Ca-alginate-immobilized hepatocyte spheroids                             2 × 10^10^     Packed-bed bioreactor                                                12h    Median survival time: Control 21 h *n* = 5 BAL 28.5 h *n* = 5 Cell-free BAL 21 h *n* = 5                                                                       Decreased: ammonia; creatinine ICP; BP Increased: urine                       NR
  29       2018       Rhesus monkey       30               M              10-20               α-amanitin and lipopolysaccharide                  SRBAL       Pig hepatocyte-HUVEC organoids                                           2.6 × 10^10^   Spheroid reservoir                                                   6 h    Median survival time: SRBAL 12 h 336 h *n* = 6 SRBAL 24 h 248 h *n* = 6 SRBAL 36 h 132 h *n* = 6 Sham no-cell SRBAL 12 h 90 h *n* = 6 Control 60.5 h *n* = 6   Decreased: ammonia; bilirubin Increased: albumin                              Negative (6 h)
  30       2019       Pig                 18               F              20-30               85% hepatectomy                                    SRBAL       Porcine hepatocyte spheroids                                             200g           Spheroid reservoir                                                   24 h   Survival rate at 90 h: SMT 0/6 SMT plus no-cell SRBAL 0/6 SMT plus SRBAL (200 g) 5/6                                                                           Decreased: ammonia; ICP; INR Increased: volume regeneration                   NR

NA: Not applicable; NR: Not reported; BAL: Bioartificial liver; Sex: Male (M) and Female (F); ELAD: Extracorporeal liver assist device; AMC-BAL: Academic medical center bioartificial liver; MELS: Modular extracorporeal liver support; BLSS: Novel bioartificial liver support system; RFB-BAL: Radial-flow bioreactor bioartificial liver; HBAL: Hybrid bioartificial liver; FBBAL: Fluidized bed BAL; HBALSS: Hybrid bioartificial liver support system; SRBAL: Spheroid reservoir bioartificial liver; hiHep: Human-induced hepatocytes; CBAs: Conjugated bile acids; PCs: Phosphatidylcholines; LPCs: Lysophosphatidylcholines; FAs: Fatty acids; SM: Sphingomyelin; ICP: Intracranial pressure; ALB: Albumin; PT: Prothrombin time; INR: International normalized ratio; PERV: Porcine endogenous retrovirus.

The types of BAL included SRBAL (*n* = 3), HBAL (*n* = 2), FBBAL (*n* = 1), UCLBAL (*n* = 1), hiHep-BAL (*n* = 1), HBALSS (*n* = 1), FBBAL (*n* = 1), and BAL (*n* = 1), using cells from porcine hepatocyte (9/12), human hepatic CL-1 cells or HepG2 cells (2/12), and HiHeps (1/12), which were all cultured using modified three-dimensional methods such as spheroids, organoid, alginate-chitosan encapsulated, and even microgravity culture, with corresponding bioreactors such as a spheroid reservoir. The mean cell mass was 2 × 10^10^, and the treatment time ranged from 3 to 24 h (mean: 9 h; Table [3](#T3){ref-type="table"}).

Compared with the control group, the survival outcomes (median survival time or survival rate) were better in the BAL group, and the biochemical metabolic function showed improvement, especially decreased ammonia levels (10/12), bilirubin levels (6/12), ICP (5/12), and PT (4/12). All the PERV test results were negative in reported studies (Table [3](#T3){ref-type="table"}).

Meta-analysis of the effects of the BAL on mortality in the clinical trials and preclinical experiments
-------------------------------------------------------------------------------------------------------

As shown in Figure [2](#F2){ref-type="fig"}, the overall effect of the BAL on mortality in the patients with ALF\[[@B6],[@B7]\] was insignificant \[BAL 97 *vs* control 98: RR (95%CI), 0.72 (0.48-1.08)\]. However, the meta-analysis of the preclinical experiments of large animals\[[@B10],[@B12],[@B29],[@B30],[@B32],[@B36]\] indicated a significant effect of the BAL \[BAL 56 *vs* control 77: RR (95%CI), 0.27 (0.12-0.62)\]. The test of heterogeneity showed no significant difference between included studies, with *I*^2^ being 0% and 41% for human clinical studies and pre-clinical experimental studies, respectively.

![Effect of bioartificial liver support systems on mortality in acute liver failure humans and large animals. The randomized controlled trials for meta-analysis included 2 clinical trials and 6 preclinical experiments with death events (or survival rate) recorded between 90 h to 7d after application of bioartificial liver support systems. M-H: Mantel-Hanszel; BAL: Bioartificial Liver; CI: Confidence interval.](WJG-25-3634-g002){#F2}

Sensitivity analyses of pooled results using an alternative effect measure (M-H OR = 0.61, 95%CI: 0.33-1.11 for humans; OR = 0.05, 0.01-0.17 for animals), pooling method (Peto fixed effects OR = 0.61, 95%CI: 0.34-1.11 for humans; OR = 0.07, 0.03-0.15 for animals), and statistical model (fixed effects M-H RR = 0.72, 95%CI: 0.48-1.08 for humans; RR = 0.24, 0.13-0.44 for animals) showed similar findings.

As shown in [Supplemental Figure](Supplemental Figure), we observed publication bias and found none in the clinical trials, and little in the preclinical experiment studies. However, it remains unclear because of the small number of included studies.

Bias risk of included RCT and non-RCT studies
---------------------------------------------

By bias assessment, all the included RCT studies were regarded as low or middle-risk overall, with 4 to 6 of 7 items listed by the Cochrane assessment standards for RCT assessed as low risk ([Supplemental Table 2](Supplemental Table 2)). For non-RCT studies, all the clinical trials among humans scored 5 or 6 (total score: 9), indicating a low or middle risk, while those of pre-clinical experiments scored a little higher, with most scoring 7 or 8 ([Supplemental Table 3](Supplemental Table 3)).

DISCUSSION
==========

Main findings and interpretations
---------------------------------

By conducting a systematic review of 18 clinical trials and 12 preclinical experiment in large animals, including a meta-analysis of selected studies, we suggest that the BAL might reduce mortality from ALF in large animals, but not in humans \[BAL *vs* control: RR (95%CI), 0.27 (0.12-0.62) for animals and 0.72 (0.48-1.08) for humans\], with no heterogeneity observed between included studies. Compared with the preclinical experiments, most of the clinical trials were conducted more than 10 years ago. Moreover, the BAL used in large animals has undergone an obvious improvement regarding the type, cell source, cell mass, and bioreactor. All the studies showed improvements in liver and renal functions, hematologic and coagulative parameters, encephalopathy index, and neurological indicators after the treatment with BAL, with neither significant adverse events nor PERV infection.

At present, whether the BAL is able to reduce mortality in the ALF population remains controversial. For example, a meta-analysis performed in 2011\[[@B8]\] indicated that BAL appeared to affect mortality in patients with ALF, while another three meta-analyses of clinical controlled trials conducted by Liu et al\[[@B37]\], Kjaergard et al\[[@B3]\], and Zheng et al\[[@B38]\] demonstrated that the use of the BAL was not associated with the improvement of survival outcome among patients with ALF, which is consistent with our study.

The quality of the BAL is the most important indicator that affects the outcome and adverse events of BAL treatment for ALF, which might support the effect difference between clinical trials and preclinical experiments. As reported in our study, cell source, culture mode, cell mass, and the bioreactor of the BAL were different between the two types of study.

There are currently four main sources of cells for the BAL and their pros and cons are as follows: (1) Human primary hepatocytes are the most suitable cells but are limited by low availability due to a shortage of donor organs\[[@B38]\]; (2) Immortalized human hepatoblastoma cell lines (HepG2/C3A/hepatic CL-1) are sufficiently expanded but are considered to have less metabolic functions than primary hepatocytes\[[@B39]\]; (3) Human-induced hepatocytes (hiHep) were reported to have a potential for metabolic detoxification\[[@B12]\], but it is difficult to meet the demands on a clinical scale because of the cost and complexity of hiHep; and (4) Porcine hepatocytes are the main cells used in the BAL and have similar function with human hepatocytes, are readily available, and are low-cost. Although no PERV infection has been found in 42 patients with long-term immunosuppression and 13 healthcare workers after a follow-up of 5-8 years by a new highly sensitive and specific quantitative real-time polymerase chain reaction assay\[[@B40],[@B41]\], xenozoonosis and the potential risks of PERV infection after treatment remain a concern.

In addition, primary hepatocytes easily lose their function *in vitro* during long-term monolayer culture\[[@B42]\]. In the preclinical experiments, to maintain and improve the viability and metabolic functions of hepatocytes, cells were cultured in a three-dimensional environment to simulate microgravity to form spheroids\[[@B30],[@B32],[@B36]\] or organoids\[[@B10]\], and alginate-chitosan encapsulated spheroids\[[@B5],[@B11],[@B33]\]. Hepatocytes were also co-cultured with bone marrow mesenchymal cells and human umbilical vein endothelial cells to maintain the function of porcine hepatocytes by providing cell-to-cell interactions\[[@B10],[@B29],[@B31],[@B43]\]. In addition, to adapt to the changes of the cells, bioreactors were modified as spheroid reservoirs and multi-layer radial-flow bioreactors to provide a suitable environment for hepatocytes to survive and maintain their cell functions.

Adequate liver cell mass is another crucial indicator for evaluating the BAL, and the innovation requires a higher number of hepatocytes and enhanced function during long-term culture\[[@B44]\]. It has been widely suggested that approximately 30% of the total liver volume is required for survival and that 10-40 billion liver cells without loss of function would be required for BAL treatment\[[@B45],[@B46]\]. Therefore, the low functionality and availability of cells for the clinical scale mass of all the BAL might explain the insignificant effect based on the meta-analysis of the two controlled clinical trials in comparison with the preclinical experiments.

Furthermore, in the preclinical experiments, the subjects in each study were the homogeneous ALF models, but in the clinical trials, the etiologies of ALF varied and were complex, which might have led to different effects of the BAL. In comparison to the patients with PNF, the patients with FHF showed a strikingly different effect of the BAL treatment in a randomized multicenter controlled trial\[[@B6]\] and two non-controlled clinical trials\[[@B14],[@B15]\]. Only unremarkable metabolic effects were observed in the patients with PNF, without amelioration of the neurological state and survival benefit after BAL treatment, whereas an improvement in neurological state and benefit were observed in the patients with FHF, even though one case report on PNF showed a great improvement in neurological state with a change in coma stage from IV to I after treatment with MELS\[[@B22]\].

Strengths and limitations
-------------------------

Our study has several strengths. First, by using a systematic searching strategy and selection procedures, we included all the clinical trials of BAL for ALF and preclinical experiments on large animals in the recent decade, which might represent a current overview of research in this domain, making our study probably the first review to provide evidence for future research. Second, we calculated the combined effect of BAL for ALF by performing a meta-analysis of RCT studies stratified according to clinical trial and preclinical experiment, making the effects comparable between the two study types; meanwhile, the bias of all the included studies was assessed as low to middle-risk and the publication bias was subtle. Finally, we created a detailed checklist of all the potential information associated with the outcome of BAL. Two independent reviewers conducted data extraction, ensuring quality data and allowing for examination of the gap between preclinical experiments and clinical trials.

Our study has two main limitations. One is that the number of RCT clinical trials included was limited to meta-analyses even if many studies have been conducted on ALF and other liver diseases such as acute-on-chronic liver failure. Nevertheless, our data could be usable. Thus, the overall effect of BAL for ALF in humans was desirable but must be verified in the future. Another limitation is that it was not necessary or proper for us to use a meta-regression for controlling covariates, because there existed no heterogeneity between included studies and the limited number of included studies did not meet the requirement of the precondition for regression. Thus, we could not provide further evidence for future research and practice.

Suggestions for future research
-------------------------------

Based on the results of our study, we suggest the following for future clinical trials, preclinical experiments, and transformations. First, alternative cells or methods for acquiring high-quality liver cells *in vitro* must be identified to achieve clinical-scale goals. Second, the effects of the subgroups, patients with PNF or FHF, and patients with different etiologies should be determined and examined in clinical trials in the future. Finally, the advanced BAL, which proved to have a significant benefit on the survival outcome of the large-animal ALF model, should undergo clinical transformation as much as possible.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Acute liver failure (ALF) has a high mortality varying from 80% to 85% with rapid progress in multi-organ system failure. Bioartificial liver (BAL) support systems have a potential effect to provide temporary support to bridge patients with acute liver failure to liver transplantation or spontaneous recovery. In the past decades, several BAL support systems have been conducted in clinical trials, but remained verified. More recently, concerns have been raised on the renovation of high-quality cell sources and configuration of BAL support systems to provide more benefits to ALF models in preclinical experiments.

Research motivation
-------------------

A systematic review and meta-analysis of the existing literature on the use of BAL among humans and large animals with ALF could help bridge the gap between preclinical experiments and clinical trials regarding the effect of BAL for treating acute liver failure.

Research objectives
-------------------

To investigate the characteristics of studies about BAL for ALF, and to evaluate their effects on mortality.

Research methods
----------------

Eligible clinical trials and preclinical experiments on large animals were identified on Cochrane Library, PubMed, and EMbase up to March 6, 2019. Two reviewers independently extracted the necessary information, including the key BAL indicators, survival and indicating outcomes, and adverse events during treatment. Descriptive analysis was used to identify the characteristics of the included studies, and a meta-analysis by including only RCT studies was performed to combine the overall effect of BAL on mortality among humans and large animal, respectively.

Research results
----------------

Of 30 selected studies, 18 were clinical trials and 12 were preclinical experiments. The meta-analysis results suggested that BAL might reduce the mortality of ALF in large animals, probably due to the recent improvement of BAL, including the type, cell source, cell mass, and bioreactor, but seemed ineffective for humans. Liver and renal functions, hematologic and coagulative parameters, encephalopathy index, and neurological indicators seemed to improve after BAL, with neither meaningful adverse events nor porcine endogenous retrovirus infection.

Research conclusions
--------------------

BAL may reduce the mortality of ALF by bridging the gap between preclinical experiments and clinical trials. Clinical trials using improved BAL must be designed scientifically and conducted in the future to provide evidence for transformation.

Research perspectives
---------------------

Our study could provide some suggestions for future clinical trials, preclinical experiments, and transformations. First, alternative cells or methods for acquiring high-quality liver cells *in vitro* must be identified to achieve clinical-scale goals. Second, the effects of the subgroups, patients with PNF or FHF, and patients with different etiologies should be determined and examined in clinical trials in the future. Finally, the advanced BAL, which proved to have a significant benefit on the survival outcome of the large-animal ALF model, should undergo clinical transformation as much as possible.
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